Untreated symptomatic VMA/VMT can lead to debilitating visual - TopicsExpress



          

Untreated symptomatic VMA/VMT can lead to debilitating visual symptoms and is a risk factor for the development of full-thickness macular holes (FTMHs). Ocriplasmin is the only approved pharmacological treatment option for patients with symptomatic VMA/VMT. It is a novel truncated form of plasmin that enzymatically cleaves structural proteins at the vitreoretinal interface, leading to liquefaction and vitreous detachment. The efficacy and safety of ocriplasmin was demonstrated by the Phase III MIVI-TRUST Study program that showed that overall, a single intravitreal injection of ocriplasmin (125 µg) resulted in a higher proportion of patients achieving VMA resolution (26.5 percent) at day 28 versus placebo (10.1 percent).
Posted on: Tue, 09 Dec 2014 15:08:01 +0000

Trending Topics



Recently Viewed Topics




© 2015